View Item 

Show simple item record

UL 54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease
dc.contributor.authorGregg, K.en_US
dc.contributor.authorHakki, M.en_US
dc.contributor.authorKaul, D.R.en_US
dc.date.accessioned2014-05-23T15:59:19Z
dc.date.available2015-06-01T15:48:45Zen_US
dc.date.issued2014-04en_US
dc.identifier.citationGregg, K.; Hakki, M.; Kaul, D.R. (2014). " UL 54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease." Transplant Infectious Disease 16(2): 320-323.en_US
dc.identifier.issn1398-2273en_US
dc.identifier.issn1399-3062en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/106875
dc.description.abstractWe present a case of foscarnet ( FOS ) resistance arising from a UL 54 mutation after a short duration of FOS exposure, which has not been previously described in a stem cell transplant recipient, to our knowledge. We discuss the use of FOS to treat other viral infections and the implications this may have for the development of resistance mutations and treatment of cytomegalovirus disease.en_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherCytomegalovirusen_US
dc.subject.otherE756K Mutationen_US
dc.subject.otherResistanceen_US
dc.subject.otherFoscarneten_US
dc.subject.otherUL 54en_US
dc.titleUL 54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus diseaseen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMicrobiology and Immunologyen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/106875/1/tid12200.pdf
dc.identifier.doi10.1111/tid.12200en_US
dc.identifier.sourceTransplant Infectious Diseaseen_US
dc.identifier.citedreferenceChou SW. Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis 2001; 3 ( Suppl 2 ): 20 – 24.en_US
dc.identifier.citedreferenceHebart H, Einsele H. Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 2004; 65 ( 5 ): 432 – 436.en_US
dc.identifier.citedreferenceLjungman P. Beta‐herpesvirus challenges in the transplant recipient. J Infect Dis 2002; 186 ( Suppl 1 ): S99 – S109.en_US
dc.identifier.citedreferenceEinsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86 ( 7 ): 2815 – 2820.en_US
dc.identifier.citedreferenceBoeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia Y. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9 ( 9 ): 543 – 558.en_US
dc.identifier.citedreferenceValcyte Prescribing Information. Genentech, Inc. Available at: www.gene.com/download/df/valcyte_prescribing.pdf. Revised March, 2013.en_US
dc.identifier.citedreferenceBacigalupo A, Boyd A, Slipper J, Curtis J, Clissold S. Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients. Expert Rev Anti Infect Ther 2012; 10 ( 11 ): 1249 – 1264.en_US
dc.identifier.citedreferenceReusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99 ( 4 ): 1159 – 1164.en_US
dc.identifier.citedreferenceLurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23 ( 4 ): 689 – 712.en_US
dc.identifier.citedreferenceScott GM, Weinberg A, Rawlinson WD, Chou S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 2007; 51 ( 1 ): 89 – 94.en_US
dc.identifier.citedreferenceChou S, Lurain NS, Thompson KD, Miner RC, Drew WL. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003; 188 ( 1 ): 32 – 39.en_US
dc.identifier.citedreferenceIshiyama K, Katagiri T, Ohata K, et al. Safety of pre‐engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation. Transpl Infect Dis 2012; 14 ( 1 ): 33 – 39.en_US
dc.identifier.citedreferenceAsakura M, Ikegame K, Yoshihara S, et al. Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor. Int J Hematol 2010; 92 ( 2 ): 351 – 359.en_US
dc.identifier.citedreferenceShapira MY, Resnick IB, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug‐resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008; 46 ( 9 ): 1455 – 1457.en_US
dc.identifier.citedreferenceBoutolleau D, Canestri A, Burrel S. Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug‐resistant HIV infection. J Clin Virol 2012; 54 ( 2 ): 194 – 196.en_US
dc.identifier.citedreferenceKotton CN, Kumar D, Caliendo AM, et al; Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid‐organ transplantation. Transplantation 2013; 96 ( 54 ): 333 – 360.en_US
dc.identifier.citedreferenceDrew WL. Cytomegalovirus resistance testing: pitfalls and problems for the clinician. Clin Infect Dis 2010; 50 ( 5 ): 733 – 736.en_US
dc.identifier.citedreferenceMyhre HA, Haug Dorenberg D, Kristiansen KI, et al. Incidence and outcomes of ganciclovir‐resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation 2011; 92 ( 2 ): 217 – 223.en_US
dc.identifier.citedreferenceGrim SA, Pereira E, Guzman G, Clark NM. CMV PCR as a diagnostic tool for CMV gastrointestinal disease after solid organ transplantation. Transplantation 2010; 90 ( 7 ): 799 – 801.en_US
dc.identifier.citedreferenceFica A, Cervera C, Perez N, et al. Immunohistochemically proven cytomegalovirus end‐organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests. Transpl Infect Dis 2007; 9 ( 3 ): 203 – 210.en_US
dc.identifier.citedreferenceIshiyama K, Katagiri T, Hoshino T, Yoshida T, Yamaguchi M, Nakao S. Preemptive therapy of human herpesvirus‐6 encephalitis with foscarnet sodium for high‐risk patients after hematopoietic SCT. Bone Marrow Transplant 2011; 46 ( 6 ): 863 – 869.en_US
dc.identifier.citedreferenceMattes FM, Hainsworth EG, Geretti AM, et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 2004; 189 ( 8 ): 1355 – 1361.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
tid12200.pdf
Size:
103.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.